Targeting PD-L1 in non-small cell lung cancer using CAR T cells
Abstract Antibodies against programmed cell death protein 1 (PD-1) and its ligand (PD-L1) have dramatically changed the landscape of therapies for non-small cell lung carcinoma (NSCLC); however, the majority of patients do not respond to these agents. In addition, hyperprogressive disease (HPD) deve...
Shranjeno v:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | angleščina |
| Izdano: |
2020
|
| Online dostop: | https://doi.org/10.1038/s41389-020-00257-z https://www.nature.com/articles/s41389-020-00257-z.pdf |
| Oznake: |
Označite
Brez oznak, prvi označite!
|
Komentirajte kot prvi!